Chengdu Easton Biopharmaceuticals Co., Ltd. (CHENGDU EASTON BIO PHARMACEUTIC) aktie

Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; Apualutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, and Ruxolitinib Phosphate for oncological applications; Bricaracetam and Lacosamide for neurological and psychiatric applications; and Empagliflozin for anti-diabetic applications. The company was founded in 2009 and is based in Chengdu, China.